MedTrace Logo

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

NCT05743036 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-08-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.

Conditions

Interventions

DRUG

ZN-c3

ZN-c3 tablet by mouth, in combination with encorafenib

DRUG

Encorafenib

Encorafenib capsule by mouth, in combination with ZN-c3

DRUG

Cetuximab

Infusion

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-07-16
Completion
2025-07-09
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Hungary
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05743036 on ClinicalTrials.gov